医学
肥厚性心肌病
心室流出道梗阻
心脏病学
梗阻性心肌病
内科学
酒精间隔消融
重症监护医学
介绍
心力衰竭的处理
心力衰竭
家庭医学
作者
Francesco Pelliccia,Ottavio Alfieri,Paolo Calabrò,Franco Cecchi,Paolo Ferrazzi,Felice Gragnano,Juan Pablo Kaski,Giuseppe Limongelli,Martin S. Maron,Claudio Rapezzi,Hubert Seggewiß,Magdi H. Yacoub,Iacopo Olivotto
标识
DOI:10.1016/j.ijcard.2020.01.021
摘要
Patients with hypertrophic cardiomyopathy (HCM) exhibit a variable phenotype with ventricular hypertrophy as the cardinal manifestation and left ventricular (LV) outflow tract obstruction (LVOTO) as a key pathophysiologic determinant. Patients with severe LVOTO usually present with exertional dyspnea, exertional syncope, and heart failure symptoms, while successful relief of LVOTO by pharmacological or invasive interventions leads to a dramatic improvement in clinical status. Proper management of obstructive HCM remains challenging and poses numerous clinical dilemmas. Since the development of surgical myectomy over half a century ago, progress in the management of LVOTO in HCM has paralleled technological advances in genetic testing, cardiac imaging, arrhythmic prophylaxis, cardiac surgery and interventional cardiology. These changes have been incorporated in dedicated scientific guidelines on both sides of the Atlantic. However, either the 2011 American guidelines or the 2014 European guidelines remain largely based on expert consensus for lack of recommendations with level of evidence A regarding any of the treatment options commonly employed in HCM. Consequently, management of obstructive HCM patients remains largely subjective and dependent on clinical judgment, local expertise, and patient preference. Following the trend that has emerged for other cardiac diseases amenable to invasive interventions, adequate evaluation and management of obstruction in HCM today requires a multidisciplinary team capable of optimizing referral, choosing the best available options, minimizing complications and ensuring state-of-the-art results. The concept of an HCM Heart Team is coming of age. This review aims to provide an update of available pharmacologic and invasive options for the management of LVOTO in HCM, either in adulthood or in childhood, highlighting areas for multidisciplinary integration and future development.
科研通智能强力驱动
Strongly Powered by AbleSci AI